Cargando…
Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability
Paclitaxel is a frontline drug for the treatment of epithelial ovarian cancer (EOC). However, following paclitaxel-platinum based chemotherapy, tumor recurrence occurs in most ovarian cancer patients. Chromosomal instability (CIN) is a hallmark of cancer and represents genetic variation fueling tumo...
Autores principales: | Raab, Monika, Sanhaji, Mourad, Zhou, Shengtao, Rödel, Franz, El-Balat, Ahmed, Becker, Sven, Strebhardt, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407080/ https://www.ncbi.nlm.nih.gov/pubmed/30851646 http://dx.doi.org/10.1016/j.neo.2019.01.007 |
Ejemplares similares
-
The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression
por: Rödel, Franz, et al.
Publicado: (2020) -
The Role of DAPK1 in the Cell Cycle Regulation of Cervical Cancer Cells and in Response to Topotecan
por: Gasimli, Khayal, et al.
Publicado: (2022) -
Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8
por: Helmke, Christina, et al.
Publicado: (2016) -
Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics
por: Noack, Sabrina, et al.
Publicado: (2018) -
Prognostic Impact of Caspase-8, CDK9 and Phospho-CDK9 (Thr 186) Expression in Patients with Uterine Cervical Cancer Treated with Definitive Chemoradiation and Brachytherapy
por: Fleischmann, Maximilian, et al.
Publicado: (2022)